Saturday 17 October 2026
Export QNRX’s income statement to Excel — free account
Quoin Pharmaceuticals, Ltd. Sponsored ADR
QNRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 69.8% and free cash flow fell 510.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.90
0.13
−3.23%
Follow QNRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(651.40%) | (141.59%) | (231.17%) | (575.73%) | |
| (154.58%) | (87.56%) | (118.61%) | (178.77%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(5,491.66%) | (109.30%) | (170.10%) | (371.60%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(18.26) | (12.68) | (5.59) | (5.39) | |
Free Cash Flow |
(10.74) | (13.54) | (15.82) | (15.27) | |
| Other line items | |||||
Cash ROIC |
(255.89%) | (42.49%) | (69.32%) | (103.67%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.78 | 0.86 | 0.93 | 0.82 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(18.26) | (12.68) | (5.59) | (5.39) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates